Skip to main content
SpringerLink
Log in

New Vaccines in Pipeline Development

  • Chapter
  • First Online:
Book cover Pediatric Vaccines and Vaccinations

  • 1231 Accesses

Abstract

  • Group B streptococcus vaccines

  • Cytomegalovirus vaccines

  • Respiratory syncytial virus vaccines

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Further Reading

  • Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Lou Manning M, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995;171:26–32. doi:10.1093/infdis/171.1.26.

    Article  CAS  PubMed  Google Scholar 

  • Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976;294(14):753–6.

    Article  CAS  PubMed  Google Scholar 

  • Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003;21(24):3468–72.

    Article  CAS  PubMed  Google Scholar 

  • Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, et al. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial. Vaccine. 2016;34:313–9. doi:10.1016/j.vaccine.2015.11.056.

    Article  CAS  PubMed  Google Scholar 

  • Brodeur BR, Boyer M, Charlebois I, Hamel J, Couture F, Rioux CR, et al. Identification of group B streptococcal sip protein, which elicits cross-protective immunity. Infect Immun. 2000;68(10):5610–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17:355–63. doi:10.1002/rmv.544.

    Article  PubMed  Google Scholar 

  • Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012;86:7444–7. doi:10.1128/JVI.00467-12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2016;213(3):411–22.

    Article  PubMed  Google Scholar 

  • Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heath PT, Schuchat A. Perinatal group B streptococcal disease. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):411–24.

    Article  PubMed  Google Scholar 

  • Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;16(5):546–55.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405–21.

    Article  CAS  PubMed  Google Scholar 

  • Lambert L, Sagfors AM, Openshaw PJ, Culley FJ. Immunity to RSV in early-life. Front Immunol. 2014;5:466.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lanzieri TM, Bialek SR, Ortega-Sanchez IR, Gambhir M. Modeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infection. Vaccine. 2014;32:3780–6. doi:10.1016/j.vaccine.2014.05.014.

    Article  PubMed  PubMed Central  Google Scholar 

  • Le Doare K, Heath PT. An overview of global GBS epidemiology. Vaccine. 2013;31(Suppl 4):D7–12.

    Article  PubMed  Google Scholar 

  • Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, et al. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One. 2013;8:e59863–13. doi:10.1371/journal.pone.0059863.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maione D, Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M, et al. Identification of a universal group B streptococcus vaccine by multiple genome screen. Science. 2005;309(5731):148–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Margarit I, Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, Buttazzoni E, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis. 2009;199(1):108–15.

    Article  PubMed  Google Scholar 

  • Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy? Curr Opin Infect Dis. 2015;28(3):221–4.

    Article  CAS  PubMed  Google Scholar 

  • Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003;21(24):3465–7.

    Article  CAS  PubMed  Google Scholar 

  • Murray J, Bottle A, Sharland M, Modi N, Aylin P, Majeed A, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One. 2014;9(2):e89186.

    Article  PubMed  PubMed Central  Google Scholar 

  • Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.

    Article  PubMed  PubMed Central  Google Scholar 

  • Neostrep. Neostrep – development of group B streptococcal vaccine. 2016 [cited 2016 .24/01/16]; Available from: ► http://www.neostrep.eu/index.html

  • Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–7.

    Google Scholar 

  • Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360:1191–9. doi:10.1056/NEJMoa0804749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • PATH. Respiratory syncytial virus. Vaccine development against a major cause of childhood respiratory illness 2016 [13/9/16]. Available from: ► http://sites.path.org/vaccinedevelopment/respiratory-syncytial-virus-rsv/.

  • Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol. 2015;204:247–54. doi:10.1007/s00430-015-0388-z.

    Article  CAS  PubMed  Google Scholar 

  • Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31(Suppl 4):D20–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Paediatric Infectious Diseases Research Group, St George’s University of London, London, UK

    Paul T. Heath, Christine E. Jones & Kirsty Le Doare

  2. University of Southampton, Southampton, UK

    Paul T. Heath, Christine E. Jones & Kirsty Le Doare

  3. Centre for International Child Health, Imperial College, London, UK

    Paul T. Heath, Christine E. Jones & Kirsty Le Doare

Authors
  1. Paul T. Heath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine E. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirsty Le Doare
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul T. Heath .

Editor information

Editors and Affiliations

  1. Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland

    Timo Vesikari

  2. Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Antwerpen, Belgium

    Pierre Van Damme

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Heath, P.T., Jones, C.E., Le Doare, K. (2017). New Vaccines in Pipeline Development. In: Vesikari, T., Van Damme, P. (eds) Pediatric Vaccines and Vaccinations. Springer, Cham. https://doi.org/10.1007/978-3-319-59952-6_24

Download citation

Publish with us

Policies and ethics

Search

Navigation